anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: In therapeutic drug monitoring (TDM) of vancomycin (VCM), the area under the concentration-time curve (AUC) is related to the clinical efficacy and toxicity. Therefore, herein, we examined the factors associated with achieving the target AUC at follow-up and developed a decision flowchart for achieving the target AUC in critically ill patients.
METHODS: This multicenter retrospective observational study was conducted at eight hospitals. We retrospectively analyzed data from patients who had received VCM in the intensive care unit from January 2020 to December 2022. Decision-tree (DT) analysis was performed using factors with p < 0.1 in univariate analysis as the independent variables. Case data were split up to two times, and four subgroups were included. The primary endpoint was achieving the target AUC at the follow-up TDM (AUCfollow-up) and target AUCfollow-up achievement was defined as an AUC of 400-600 μg‧h/mL. The initial AUC values were calculated with the 2-point concentrations (peak and trough) using the Bayesian estimation software Practical AUC-guided TDM (PAT).
RESULTS: Among 70 patients (median age [interquartile range], 66 [56, 79] years; 50 % women), the AUCfollow-up was achieved in 70 % (49/70). Three factors were selected for the decision flow chart: predicted AUCfollow-up of 400-600 μg‧h/mL, dosing at 12-h intervals, and CCr of 130 mL/min/1.73 m2 or higher; the accuracy was adequate (92 %, R2 0.52).
CONCLUSION: We successfully identified the factors associated with achieving the target AUC of VCM at follow-up TDM and developed a simple-to-use DT model. However, the validity of the findings needs to be evaluated.
The invention concerns a new mutant of η-IFN. This new polypeptide contains 134 amino acids. Amino acids 1 to 132 are the same as those of natural η-interferon. The first amino acid, methionine, in the zero position is also present, as has been demonstrated by protein sequencing. The amino acid in position 133 is leucine instead of glutamine. The invention also concerns DNA sequences and plasmid DNA (DSM 6238) which codes for this new polypeptide. The invention further concerns the use of the polypeptide as a drug as well as its use as a fine-chemical reagent for in vitro experiments.
Dyads of participants in the control group will receive 3-session health talks. One hour for each session, and once weekly. The contents of the health talks are neither dementia-specific nor related to ACP, and cover general health information for elderly, such as drug safety, home safety, exercise and health. This is to differentiate the effect of the intervention from the effect of the extra time and attention given to the participants.
1,244,320. Pyridine carboxylic acid amides. SOC. D'ETUDES ET APPLICATIONS CHIMIQUES, and C. DUFOUR. 16 Dec., 1968 [3 April, 1968; 12 April, 1968; 25 Nov., 1968; 4 Dec., 1968], No. 59764/68. Addition to 1,235,348. Heading C2C. Novel pyridine carboxylic acid amides of the formula in which R is one or more H, Cl, Br, I or F atoms, one or more OH groups, one or more C 1-4  acyloxy groups, or COOH, carboxamide, or carboxylic acid ester sulphonic or sulphamoyl group or groups, or C 1-8 hydrocarbon group or groups, or a salt therefore with a mineral or organic acid or quaternary ammonium salt thereof, provided that when R is a hydrogen atom said amide is in the form of one of said salts are prepared by reacting corresponding acid or reactive derivative with cyclopropylamine. Alternatively the novel compounds may be prepared by the direct introduction of the substituent R into the pyridine ring of the appropriate N-cyclopropyl amide derivative. 2-Chloronicotinic acid chloride is obtained by reacting 2-chloronicotinic acid hydrochloride with thionyl chloride. Pharmaceutical compositions, having diuretic hypotensive and sedative activities and suitable oral or parenteral administration, contain the above novel compounds or salts thereof and pharmaceutically acceptable carriers.
Moderate and late preterm infants contribute to significant neonatal intensive care unit health care resource utilization because of their sheer numbers. Determinants of the length of hospitalization in this population are understudied. Gestational age is used most commonly as a predictor for length of hospital stay but there are many limitations including inaccurate dating and morbidities of prematurity which at least partly related to neurophysiological immaturity. The latter can be assessed by amplitude integrated electroencephalogram (aEEG, a simplified 5 lead EEG), and possibly by heart rate variability (HRV). Both non-invasive tests that can be done at the bedside. The study hypothesis is to determine if neurophysiologic maturation as assessed by aEEG and HRV within 24-96 hours following birth improves the correlation between gestational age and time to reach milestones for safe discharge, such as thermal regulation and oral-motor skills for adequate nutritional intake, compared to gestational age alone.
The invention relates to a fast-effect bone-knitting medicine. The characteristic weight of the medicine is as follows: the medicine has two types, one of which is for oral administration and the other of which is for external use. The oral administration contains 40 to 50 grams of angelica, 15 to 18 grams of lignum dalbergiae odoriferae, 50 to 60 grams of ground bettle, 10 to 20 grams of frankincense and 50 to 60 grams of copper sand. The medicine for external use has 10 to 20 grams of lignum dabergiae odriferae, 10 to 20 grams of the frankincense, 10 to 20 grams of myrrh, 10 to 15 grams of resina draconis and 10 to 15 grams of cutch. The medicine adopts a comprehensive method of internal and external treatment, thus having a fast-effect magic effect on the treatment of bone fracture. As a result, the pain of a patient can be relieved quickly and the patient can recover soon with spending little expenses.
The worldwide Human Immunodeficiency Virus / Acquired Immunodeficiency Syndrome (HIV/AIDS) epidemic may only be controlled through development and utilization of a safe and effective vaccine that will prevent HIV infection. Due to the high prevalence of HIV-1 subtype C in southern Africa, the South African AIDS Vaccine Initiative (SAAVI), the HIV Vaccine Trials Network (HVTN), Novartis, and the National Institute of Allergy and Infectious Diseases (NIAID) are evaluating three subtype C HIV vaccines, SAAVI DNA-C2, SAAVI MVA-C, and Novartis Subtype C gp140 through this study. These vaccines will be used together in four prime-boost regimens. The SAAVI DNA-C2 vaccine is a multigene deoxyribonucleic acid (DNA) vaccine consisting of two DNA plasmids in equal amounts that express an HIV-1 subtype C polyprotein comprising of Gag-Reverse Transcriptase-Tat-Nef and an HIV-1 subtype C truncated Env. SAAVI MVA-C is a recombinant modified vaccinia Ankara (MVA) vaccine expressing the same immunogens as the SAAVI DNA-C2 vaccine. MVA is a highly attenuated vaccinia virus. The Novartis protein subunit vaccine is a Subtype C oligomeric V2 loop deleted glycoprotein 140 (gp140) vaccine (gp140\[delta\]V2.TV1), given with MF59 adjuvant.

This trial is designed to build upon the Thai RV144 HIV vaccine trial, which demonstrated an efficacy of 31.2% among participants who received a different vaccine regimen of a pox prime followed by a concurrently-administered protein boost. This primary purpose of HVTN 086 is to evaluate the safety and immunogenicity of SAAVI DNA-C2, SAAVI MVA-C and Novartis Clade C gp140TV1ΔV2 with MF59 adjuvant in various vaccination regimens. The primary analysis will focus on a ranking strategy of the vaccine regimens that is guided by measurements of the immune responses elicited by these vaccines and their respective modes of delivery in various combinations, both sequential and concurrent.

Participants will actively participate in this study for 12 months. Participants will be randomly assigned to receive either a prime-boost preventive vaccine regimen or placebo. Four prime-boost preventive vaccine regimens will be compared; each participant will be randomized to one of 4 groups. Participants in Group 1 will receive MVA-C at months 0 and 1, and gp140/MF59 at months 3 and 6. Group 2 will receive MVA-C and gp140/MF59 at months 1 and 3. Group 3 will receive DNA-C at months 0 and 1, and MVA-C at months 3 and 6. Group 4 will receive DNA-C at months 0 and 1, and both MVA-C and gp140/MF59 at months 3 and 6. Additional study visits will occur at Weeks 2, 6, 13, 14, 26, 28, 36, and 48. All participants will be contacted once annually for 3 years and asked questions about their health. Study procedures include physical exams, blood and urine collection, HIV testing, an electrocardiogram, and questionnaire. Some blood collected from participants will be stored and used in future research. Risk-reduction counseling will be conducted at all study visits.
Several clinical trials are currently under way evaluating the safety and effectiveness of ARV-based PrEP for preventing HIV infection. The results of the first efficacy trials of ARV-based PrEP showed fewer HIV infections among study participants receiving the study drugs compared to those receiving placebo. Although the results are promising, concerns about adherence, pharmacokinetics, and toxicity still needs further exploration so new and more effective preventive pharmacological approaches should be evaluated. This trial will evaluate the safety, pharmacokinetics and efficacy of ex vivo HIV infection of rectal mucosa by the CCR5 antagonist drug maraviroc (Selzentry) administered to healthy volunteers. This trial will last approximately one year. Twenty-one volunteers will receive MVC 300 mg orally in a single dose. Study visits will occur at enrollment and at days 0, 7, 9, 14 and 16. All study visits will include a physical examination, blood collection and storage and in the basal visit and a day 7 or 9 the participants will undergo a colonoscopy. Ex vivo HIV infectivity in rectal mucosa biopsies and plasma/mucosa MVC levels will be evaluated.
The present invention discloses a composite propolis health care product and a preparation method thereof. The health care product is mainly prepared from propolis extract, Ginkgo leave extract, vitamin E and corn oil according to certain proportion. The preparation method comprises the steps that active ingredients of propolis and Ginkgo leaves are extracted by ethanol under certain conditions, and then an extract is obtained by condensing the active ingredients when pressure is reduced. After a baking procedure and a mesh screening procedure, the manufactured propolis extract powder and the Ginkgo leaf extract powder are mixed with a certain amount of vitamin E and corn oil. The heal care product can be made into soft capsules. The composite propolis health care product has no toxicity and the actions of improving immunity, adjusting blood fat concentration, etc.
PROBLEM TO BE SOLVED: To provide a method for conveniently, rapidly and safely color hair by coating non-permanent keratinous fibers, especially hair on the human scalp with a specific coloring polymer. SOLUTION: A sulfo-containing water-dispersible type coloring polymer containing a colorant moiety reacted into a carbonyloxy group and/or carbonylamide group skeleton of the polymer is used. The polymer contains 20-100 mol.% carbonyloxy linking groups and further 0-80 mol.% carbonylamide linking groups and the colorant is composed of a heat stable organic compound having condensable groups and contained in an amount of 1-40 mol.% based on the total of all reactant hydroxy, carboxy and amino and amino equivalents and the condensable derivatives thereof. The hair coloring composition containing the polymer is capable of carrying out non-permanent hair coloring. Although the coloring is readily removed with hot water, e.g. a shampoo, the polymer remarkably manifests resistance to redispersion in water at ambient temperature without causing flaking of hair or color rub-off.
BACKGROUND: The viral load (VL) in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected individuals is critical for improving clinical treatment strategies, care, and decisions. Several studies have reported that the initial SARS-CoV-2 VL is associated with disease severity and mortality. Cycle threshold (Ct) values and/or copies/mL are often used to quantify VL. However, a multitude of platforms, primer/probe sets of different SARS-CoV-2 target genes, and reference material manufacturers may cause inconsistent interlaboratory interpretations. The first International Standard for SARS-CoV-2 RNA quantitative assays has allowed diagnostic laboratories to transition SARS-CoV-2 VL results into international units per milliliter (IU/mL). The Cobas SARS-CoV-2 Duo quantitative assay provides VL results expressed in IU/mL.
MATERIALS AND METHODS: We enrolled 145 and 50 SARS-CoV-2-positive, hospitalized and 50-negative individuals at the Tri-Service General Hospital, Taiwan from January to May 2022. Each participant's electronic medical record was reviewed to determine asymptomatic, mild, moderate, and severe cases. Nasopharyngeal swabs were collected using universal transport medium. We investigated the association of SARS-CoV-2 VL with disease severity using the Cobas SARS-CoV-2 Duo quantitative assay and its functionality in clinical assessment and decision making to further improve clinical treatment strategies. Limit of detection (LOD) was assessed.
RESULTS: All 50 SARS-CoV-2-negative samples confirmed negative for SARS-CoV-2, demonstrating 100 % specificity of the Cobas SARS-CoV-2 Duo assay. Patients with severe symptoms had longer hospital stays, and the length of hospital stay (30.56 days on average) positively correlated with the VL (8.22 ± 1.21 log10 IU/mL). Asymptomatic patients had the lowest VL (5.54 ± 2.06 log10 IU/mL) at admission and the shortest hospital stay (14.1 days on average).
CONCLUSIONS: VL is associated with disease severity and duration of hospitalization; therefore, its quantification should be considered when making clinical care decisions and treatment strategies. The Cobas SARS-CoV-2 Duo assay provides a commutable unitage IU/mL for interlaboratory interpretations.
Anorexia nervosa (AN) is a serious illness associated with substantial morbidity and a mortality rate among the highest of any psychiatric illness. The rate of relapse is disturbingly high, with up to 50% of patients requiring re-hospitalization within a year of discharge. Current treatments are inadequate in helping older adolescents and adults achieve sustained recovery. Importantly, eating behavior remains disturbed after weight restoration: patients demonstrate restrictive eating in their self-selected foods and in standardized meals, and caloric intake in standardized meals is inversely related to pre-meal anxiety. Emerging data suggest that eating behavior is particularly important in post-hospital course, and that significantly altering eating behavior is critical in improving outcome for these individuals. Furthermore, caloric intake in standardized meals has been shown to be related to pre-meal anxiety. This study evaluates the potential utility of two psychotherapeutic interventions in improving eating behavior prior to hospital discharge. Each individual receives, in random order, Cognitive Remediation Therapy for 4 weeks and Exposure and Response Prevention for AN for 4 weeks. The investigators hypothesize that these interventions will lead to improvement in eating behavior, measured by food diaries and standardized meals.
In gLiFE, the same LiFE activities as performed in iLiFE are introduced and taught in 7 group sessions with 8 to 12 participants. Implementation and habitualization strategies will be addressed within the group setting, making use of group dynamics and processes.
INTRODUCTION: Colorectal cancer is the second most common cause of cancer death worldwide. Screening colonoscopy is a very effective measure to prevent colorectal cancer and can reduce mortality at the population level. However, the participation rates of screening programs are low.To provide easily accessible information on screening colonoscopy and to increase the participation rates of screening programs, we developed a questionnaire for asymptomatic patients based on the German guidelines to assess the indication for screening colonoscopy. We evaluated the questionnaire with reference to the indications given by specialists in gastroenterology.
METHODS: Patients who visited a specialist in gastroenterology in an outpatient clinic of a tertiary hospital for other reasons than a colonoscopy were eligible for the study. A maximum of seven questions to assess the indication for screening colonoscopy were answered by the patients. Afterward, the indication for screening colonoscopy was given or not by a specialist in gastroenterology. The accuracy of the questionnaire was measured in terms of sensitivity, specificity, and predictive values.
RESULTS: In total, 335 patients were included in the analyses, of whom 50 and 285 patients were given and were not given an indication for screening colonoscopy by the specialists, respectively. In 0/50 patients, the questionnaire was false negative and in 8/285 patients false positive. Thus, the questionnaire had a sensitivity of 100% (95% confidence interval: 93-100%), a specificity of 97% (95-99%), a negative predictive value of 100% (99-100%), and a positive predictive value of 86% (75-94%).A subgroup analysis including patients who had never had a colonoscopy (n=109) showed comparable results: sensitivity of 100% (92-100%), specificity of 92% (83-97%), negative predictive value of 100% (94-100%), and positive predictive value of 90% (87-97%).
CONCLUSION: The self-assessment questionnaire for asymptomatic individuals to assess the recommendation for screening colonoscopy is very sensitive and specific compared to a specialist in gastroenterology.The questionnaire can be found at: https://www.interdisziplinaere-endoskopie.mri.tum.de/de/infos-patienten/index.php.
Obesity is a metabolic disorder with excessive body fat accumulation, increasing incidence of chronic metabolic diseases. Hypertrophic obesity is associated with local oxidative stress and inflammation. Herein, we evaluated the in vitro activity of micromolar concentrations of α-lipoic acid (ALA) on palmitic acid (PA)-exposed murine hypertrophic 3T3-L1 adipocytes, focussing on the main molecular pathways involved in adipogenesis, inflammation, and insulin resistance. ALA, starting from 1 µM, decreased adipocytes hypertrophy, reducing PA-triggered intracellular lipid accumulation, PPAR-γ levels, and FABP4 gene expression, and counteracted PA-induced intracellular ROS levels and NF-κB activation. ALA reverted PA-induced insulin resistance, restoring PI3K/Akt axis and inducing GLUT-1 and glucose uptake, showing insulin sensitizing properties since it increased their basal levels. In conclusion, this study supports the potential effects of low micromolar ALA against hypertrophy, inflammation, and insulin resistance in adipose tissue, suggesting its important role as pharmacological supplement in the prevention of conditions linked to obesity and metabolic syndrome.
Patients receive adenovirus p53 construct by percutaneous injection to a maximum of two lesions on day 1. Treatment is repeated every 28 days for up to 6 courses. In the absence of dose-limiting toxicity (DLT) in the first cohort of 6 patients treated, subsequent cohorts of 6 patients each receive escalating doses of the drug on the same schedule. If DLT occurs in 2 of 6 patients at a given dose level, then dose escalation ceases and that dose is declared the maximum tolerated dose. Study treatment may continue in the absence of disease progression and unacceptable adverse events.
The skin treatment balm contains, in 100 parts by weight, 35 to 85 parts by weight of at least one of vegetable oils and/or fats and 10 to 35 parts by weight of at least one of fats and/or waxes of animal origin. Further, it comprises an extract of at least two plants and a biologically active substance stabilizing the preparation. The vegetable oil and/or fat is preferably rapeseed and/or sunflower, and/or olive, and/or evening primrose oil, and/or linseed, and/or coconut oil, and/or shea butter. The fat and/or wax of animal origin is preferably lanolin and/or beeswax. The plant extracts are preferably extracts of witch hazel and/or pot marigold, and/or aloe, and/or sage, and/or yarrow, and/or agrimony and/or arnica, and/or tea tree, and/or chamomile. The biologically active substance stabilizing the preparation is preferably tocopherol and/or panthenol, and/or bee propolis, and/or grapefruit seed extract.
PURPOSE:The titled sustained release preparation having a microspherical structure usable for injection or implantation, capable of keeping always a constant concentration of drug activity during a necessary period, controlling a release rate of drug, comprising a polylactic acid, an additional matter, and a drug. CONSTITUTION:A drug such as a carcinostastic, etc. is blended with a fat-soluble additional matter such as preferably fatty acid ester, etc. soluble in an organic solvent to dissolve a polylactic acid, digestible in organisms, the additional matter is added to control release rate of the drug, the blend and a high polymer decomposable in organisms comprising a polylactic acid as a main ingredient are uniformly solidified, precipitated, and prepared in a granular state, to give a sustained release preparation having a microspherical structure with 10-500mu particle diameter wherein the drug to be released prolongably is uniformly dispersed. Insulin, prostaglandin, etc. may be used as the drug. EFFECT:Both a polylactic acid and an additional matter are hydrolyzed with enzymes in organisms into harmless substances, removal of them out of body is not required, and they do not remain in body.
Several lines of evidence support protocol-driven care using a multidisciplinary approach with special focus on periodic assessments, reinforcement of compliance and attainment of treatment targets improves risk factor control and reduces morbidity and mortality in people with diabetes mellitus The Joint Asia Diabetes Evaluation (JADE) Program is an innovative project using state of the art information technology with internet on-line system to enable doctors, nurses and other medical personnel to manage people with diabetes. It provides a virtual platform to facilitate implementation of evidence-based clinical protocols and to collect, manage and analyse data to track performance for quality assurance and improvement purposes. The JADE Program incorporates validated risk equations developed by the CUHK Diabetes Care \& Research Group to stratify patients into various risk clusters for recommendation into different care protocols. This information can be relayed to people with diabetes in an interactive manner, in the form of charts and time trends, to motivate changes in behaviour and to attain treatment targets.

In this implementation project, we aim to recruit 600 type 2 diabetic patients managed in a community setting. With written informed consent, these patients will be invited to enrol into the JADE Program. All patients will undergo annual comprehensive assessment (CA) at a diabetes centre with personalized JADE report (JADE) for 3 years. Half of the patients will be managed according to the JADE protocol implemented with additional support by a trained CHW (JADE+CHW). Guided by the personalized report with embedded decision support, the CHW will reinforce treatment adherence and self care after each clinic visit.